title: Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics.
abstract: The immunomodulatory effects of indoleamine 2,3-dioxygenase (IDO) are ascribed to its ability to catalyze breakdown of the essential amino acid L-tryptophan. We applied reverse transcription-polymerase chain reaction (RT-PCR) to examine IDO mRNA expression in acute myeloid leukemia (AML) blasts, and investigated its clinical significance. We enrolled 62 patients with AML between April 2005 and March 2013. Bone marrow-derived mononuclear fractions were separated and extracted mRNA was amplified by PCR. RT-PCR showed that the bone marrow of 23 patients expressed IDO mRNA but not in 39. IDO mRNA expression did not significantly differ among cytogenetic risk profiles. The 3-year overall survival rates for patients with and without IDO mRNA expression were 39% and 74%, respectively (p < 0.005). The rates for patients with intermediate-risk cytogenetics with and without IDO mRNA expression were 16% and 70%, respectively (p < 0.005). The expression of IDO mRNA was associated with a poor prognosis of AML.
authors.affiliation: First Department of Internal Medicine.
authors.forename: Kenji
authors.initials: K
authors.lastname: Fukuno
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hara
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Shibata
authors.forename: Ryoko
authors.initials: R
authors.lastname: Mabuchi
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Nakamura
authors.forename: Junichi
authors.initials: J
authors.lastname: Kitagawa
authors.forename: Masahito
authors.initials: M
authors.lastname: Shimizu
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Ito
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Saito
authors.forename: Hisataka
authors.initials: H
authors.lastname: Moriwaki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D002869:Chromosome Aberrations; D005260:Female; D020440:Gene Duplication; D015973:Gene Expression Regulation, Leukemic; D020022:Genetic Predisposition to Disease; D006801:Humans; D016130:Immunophenotyping; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000235:genetics*; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D020080:Tandem Repeat Sequences; D055815:Young Adult; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics
chemical_list: D015415:Biomarkers; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3
keywords: Immunological tolerance; acute myeloid leukemia; indoleamine 2,3-dioxygenase; l-tryptophan catabolism; prognostic factor